With a product in one Phase III trial and about to start another in peripheral bypass graft surgery, Corgentech Inc. took an infusion of $50 million in Series C financing that gives it enough cash to last "through the first or second quarter of 2004," said Richard Powers, vice president and chief financial officer. (BioWorld Today)